Claims for Patent: 8,772,338

Summary for Patent: 8,772,338

Title:	Enhanced bimatoprost ophthalmic solution
Abstract:	A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
Inventor(s):	Chang; Chin-Ming (Tustin, CA), Chang; James N. (Newport Beach, CA), Schiffman; Rhett M. (Laguna Beach, CA), Jordan; R. Scott (Trabuco Canyon, AZ), Chang-Lin; Joan-En (Tustin, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	13/827,774
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,772,338
Patent Claims:	1. A method of lowering intraocular pressure in a person with glaucoma or ocular hypertension, the method comprising administering once daily to an eye of the person a first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride. 2. The method of claim 1, wherein the method lowers intraocular pressure as effectively and results in less hyperemia as compared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride. 3. The method of claims 1 or 2, wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride. 4. The method of claim 2, wherein the first composition further comprises dibasic sodium phosphate. 5. The method of claim 4, wherein the first composition further comprises citric acid monohydrate. 6. The method of claim 5, wherein the first composition further comprises sodium chloride. 7. The method of claim 6, wherein the first composition further comprises hydrochloric acid and sodium hydroxide to adjust the pH. 8. The method of claim 7, wherein the first composition further comprises water. 9. The method of claim 1, wherein the first composition has a pH of about 7.3. 10. A method of lowering intraocular pressure in a person with glaucoma or elevated intraocular pressure, the method comprising administering at least once daily to an eye of the person a first composition comprising 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride and having a pH of about 7.3, wherein the method lowers intraocular pressure and results in less hyperemia as compared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride. 11. The method of claim 10, wherein the first composition lowers intraocular pressure as effectively as the second composition. 12. The method of claim 10, wherein the first composition further comprises dibasic sodium phosphate heptahydrate. 13. The method of claim 12, wherein the first composition further comprises citric acid monohydrate. 14. The method of claim 13, wherein the first composition further comprises sodium chloride. 15. The method of claim 14, wherein the first composition further comprises hydrochloric acid and sodium hydroxide to adjust the pH. 16. The method of claim 15, wherein the first composition further comprises water. 17. The method of claim 10, wherein the first composition has a pH of 7.3. 18. The method of claim 10, wherein the first composition is administered once daily. 19. The method of claim 10, wherein the method is effective in controlling elevated intraocular pressure in patients and lowering elevated intraocular pressure to acceptable levels. 20. The method of claim 10, wherein the method is effective in treating glaucoma.